Myriad kept at buy by Merrill

Merrill Lynch analyst David Munno maintained Myriad Genetics Inc. at its buy rating after the company reported continued strong predictive medicine revenues, with a 7% sequential increase in sales to $30.9 million from $28.3 million. Profitability in the predictive medicine business was also better than expected, thanks to higher gross margins. Myriad announced two new tests will be available for its franchise in 2007. Shares of the Salt Lake City biopharmaceutical company were down $1.45, or 5.08/%, at $27.11. (Nasdaq: MYGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.